The amendment of the manufacturing licensing agreement between Kiora Pharmaceuticals and Sentrx Animal Care eliminates $4.75 million in near-term milestones that Kiora would have owed to Sentrx. This is a positive development for Kiora Pharmaceuticals as it reduces their financial obligations, potentially improving their short-term financial position and making the stock more attractive to investors.